Meeting Series


Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Clinical Practice Guidelines

A Guide to Comprehensive Hepatitis C Counseling and Testing.

Centers for Disease Control and Prevention.

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 

American Association for the Study of Liver Diseases/Infectious Diseases Society of America, 2017. 

Hepatitis C: Screening.

U.S. Preventive Services Task Force, 2013. 

Clinical Resources for HCV Treaters

Drugs, Brains, and Behavior: The Science of Addiction: Treatment and Recovery.

National Institute on Drug Abuse, 2014.

Harm Reduction Coalition. 

The Science of Drug Abuse and Addiction: The Basics.

National Institute on Drug Abuse, 2016.

Today’s Heroin Epidemic.

Centers for Disease Control and Prevention, 2015.

Viral Hepatitis Surveillance — United States, 2015. 

Centers for Disease Control and Prevention, 2015. 

Clinical Resources for Addiction Services Providers

Hepatitis C Infection.

American Society of Addiction Medicine, 2017.

A Medical Provider Guide: Screening for Hepatitis C Infection in People Who Inject Drugs.

Project Inform.

Patient Resources

Getting Off Right: A Safety Manual for Injection Drug Users.

The Harm Reduction Coalition has produced a compilation of unbiased medical facts, injection techniques, and common sense, with the goal of reducing harm and promoting individual and community health.

Hep C 123: Diagnosis, Treatment & Support.

American Liver Foundation, 2017. The American Liver Foundation’s Hep C 123 website is a dedicated online information and resource center created in support of individuals impacted by HCV infection.

Hepatitis C and Injection Drug Use.

The CDC is a division within the US Department of Health and Human Services (DHHS), the principal agency for protecting the health of all Americans. This webpage provides concise information regarding HCV risk, transmission, and prevention in people who inject drugs.

Hepatitis C FAQs for the Public.

The CDC is a division within the US Department of Health and Human Services (DHHS), the principal agency for protecting the health of all Americans. This patient-directed website addresses basics across the HCV clinical continuum. is a website for people living with HCV that offers education, tools, and resources. Articles are written by people living with or cured of HCV, patient advocates, and medical providers. 

The Body Pro: Spotlight Center on Hepatitis C.

Hepatitis C Prevention for People Who Inject Drugs, 2016. This article provides real-world best practices for preventing HCV infection.

Pill-Reminder Smartphone Apps (Free)

Mango Health — Medicine Manager, Pill Reminder

iPhone  and Android

Medisafe Pill Reminder, RX & Medicine Tracker

iPhone and Android

Suggested Readings

Awareness of HCV infection among persons who inject drugs in San Diego, California.

Collier MG, et al. Am J Public Health. 2015;105(2):302–303.

Doing the math on hepatitis C virus treatment.

Mehta SH, Thomas DL. J Hepatol. 2016;65(1):5-6.

Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.

McLellan AT, et al. JAMA. 2000;284(13):1689-1695.

Efficacy and safety of edipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials.

Grebely J, et al. Clin Infect Dis. 2016;63(11):1405-1411.

Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials.

Grebely J, et al. Clin Infect Dis. 2016;63(11):1479-1481.

Elbasvir/grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial.

Dore GJ, et al. Ann Intern Med. 2016;165(9):625-634.

Emerging and underrecognized complications of illicit drug use.

Wurcel AG, et al. Clin Infect Dis. 2015;61(12):1840-1849.

Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.

Rich ZC, et al. BMC Public Health. 2016;16:994.

Hepatitis C virus serosorting in people who inject drugs: sorting out the details.

Kim AY, Page K. J Infect Dis. 2013;208(12):1929-1931.

Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.

Islam N, et al. Lancet Gastroenterol Hepatol. 2017;2(3):200-210.

Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection.

Gonzalez SA, et al. Addict Disord Their Treat. 2017;16(2 suppl 1):S1-S23.

National Viral Hepatitis Action Plan 2017–2020.

U.S. Department of Health and Human Services, 2017.

Outcomes from a large 10-year hepatitis C treatment programme in people who inject drugs: no effect of recent or former injecting drug use on treatment adherence or therapeutic response.

Elsherif O, et al. PLoS One. 2017;12(6):e0178398.

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy.

Grebely J, et al. European Association for the Study of the Liver. The International Liver Congress™ − EASL 2017. April 19-23, 2017; Amsterdam, The Netherlands.

Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.

Bruneau J, et al. Clin Infect Dis. 2014;58(6):755-761.

The cost-effectiveness of harm reduction.

Wilson DP, et al. Int J Drug Policy. 2015:26(suppl 1):S5-S11.

The HCV care continuum does not end with cure: a call to arms for the prevention of reinfection.

Falade-Nwulia O, Sulkowski M. J Hepatol. 2017;66(2): 267-269.

Treating Medicaid patients with hepatitis C: clinical and economic impact.

Younossi Z, et al. Am J Manag Care. 2017;23(2):107-112.

Treatment of HCV in persons who inject drugs: treatment as prevention.

Grebely J, Dore GL. Clin Liver Dis. 2017;9(4):77-80.

Interactive Presentation

Have You Ever Injected Drugs? What You Need to Know About Hepatitis C

Current or past injection drug use puts you at high risk for hepatitis C infection. But there is good news for those who are infected: New treatments are available that cure most people—even injection drug users. This video provides important information on your risk for Hepatitis C, getting tested, and—if you're infected—getting cured.


Building Bridges to Reach People Who Inject Drugs with the Goal to Eliminate HCV

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist


Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice